Lv2
160 积分 2025-01-21 加入
First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib
23天前
已完结
Whole‐genome Sequencing of an Aggressive BRAF Wild‐type Papillary Thyroid Cancer Identified EML4–ALK Translocation as a Therapeutic Target
23天前
已完结
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying theBRAFK601EMutation
24天前
已完结
Identification of Oncogenic Alterations in 124 Cases of Pediatric Papillary Thyroid Carcinoma: BEND7::ALK, DLG5::RET, and CCDC30::ROS1 Fusions Induce MAPK Pathway Activation
26天前
已完结
Genetic landscape of papillary thyroid carcinoma in the Chinese population
27天前
已完结
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
1个月前
已完结
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance
2个月前
已完结
Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China
2个月前
已完结
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas
2个月前
已完结
A comparison of the histopathologic features of thyroid carcinomas with NTRK fusions to those with other malignant fusions
2个月前
已完结
皖公网安备34019202002308
